Comparison
Ipamorelin vs Modafinil
Side-by-side of Ipamorelin and Modafinil. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Ipamorelin
Ipamorelin peptide benefits: selective ghrelin-receptor GHRP, 200 to 300 mcg dosage, GH pulse without cortisol or prolactin rise, CJC-1295 stack vs sermorelin.
Modafinil
Modafinil cognitive enhancement profile: wakefulness-promoting agent, 100-200 mg dosing, 12-15 hour half-life, off-label nootropic use, Schedule IV status.
Effects at a glance
Ipamorelin
- •Pentapeptide GHS-R1a agonist with the cleanest selectivity profile in the GHRP class
- •Minimal cortisol and prolactin elevation at standard doses (substantially less than GHRP-2 or hexarelin)
- •~2 hour plasma half-life, longest of the synthetic GHRPs
- •Largest human safety database (~600 participants in Helsinn's postoperative ileus phase 2)
- •Standard pairing for CJC-1295 no-DAC at 200 to 300 mcg subcutaneously 2 to 3 times daily
- •Banned by WADA under S2; never reached registration despite phase 2b development
Modafinil
- •FDA approved in 1998 for narcolepsy, with later additions for shift-work sleep disorder and OSA residual sleepiness
- •Schedule IV controlled substance in the US; prescription-only in EU, UK, Australia
- •Increases wakefulness via weak dopamine reuptake inhibition plus histaminergic, noradrenergic, and orexinergic activation
- •Long half-life of 12 to 15 hours requires morning dosing to avoid sleep disruption
- •Modest cognitive enhancement signal in non-sleep-deprived adults at 100 to 200 mg (Battleday meta-review 2015)
- •Substantial CYP3A4 induction reduces hormonal contraceptive efficacy; barrier methods recommended
Side-by-side
| Attribute | Ipamorelin | Modafinil |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Provigil, Modalert, Modvigil, diphenylmethylsulfinyl-acetamide |
| Half-life (hr) ↗ | 2 | 13 |
| Typical dose (mg) ↗ | 0.2 | 200 |
| Dosing frequency | 2-3x daily | daily, morning |
| Routes | subcutaneous, intravenous | oral |
| Onset (hr) | 0.25 | 1 |
| Peak (hr) | 1 | 3 |
| Molecular weight | 711.86 | 273.35 |
| Molecular formula | C38H49N9O5 | C15H15NO2S |
| Mechanism | Selective GHS-R1a agonist that stimulates pulsatile GH release with minimal cortisol or prolactin co-activation. Suppresses hypothalamic somatostatin and stimulates pituitary somatotrophs. | Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake-promoting systems. |
| Legal status | Not FDA approved; advanced through phase 2b in postoperative ileus before discontinuation; research-use-only grey market; banned by WADA | Schedule IV (US); prescription-only globally; not a supplement |
| WADA status | banned | banned |
| DEA / Rx | Not scheduled (research chemical) | Schedule IV |
| Pregnancy | Insufficient data; not recommended | Not recommended |
| CAS | 170851-70-4 | 68693-11-8 |
| PubChem CID | 11338566 | 4236 |
| Wikidata | Q1666741 | Q422968 |
Safety profile
Ipamorelin
Common side effects
- injection-site irritation
- vivid dreams
- transient mild head pressure
- occasional headache
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
Interactions
- CJC-1295: synergistic GH release via parallel GHRH and ghrelin pathways; standard pairing(minor)
- sermorelin: additive GH release; functionally similar pairing to CJC-1295 with shorter GHRH half-life(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
Modafinil
Common side effects
- headache
- nausea
- anxiety
- insomnia (with late-day dosing)
- dry mouth
- mild blood pressure elevation
Contraindications
- recent myocardial infarction
- unstable angina
- left ventricular hypertrophy
- significant arrhythmia
- history of Stevens-Johnson syndrome
- psychotic disorders
- pregnancy
- concurrent MAOI use
Interactions
- hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
- cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
- warfarin: CYP2C9 inhibition raises INR(moderate)
- phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
- MAOIs: potential hypertensive reaction(major)
- classical stimulants (amphetamine, methylphenidate): additive cardiovascular and sleep-disruption effects(moderate)
Which Should You Take?
Modafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Ipamorelin is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick Ipamorelin.
- → If your priority is post-training recovery, pick Ipamorelin.
- → If your priority is wakefulness, pick Modafinil.
- → If your priority is focus or working memory, pick Modafinil.
Edge case: If you cannot self-administer injections, Modafinil is the only oral option in this pair.
Default choice: Modafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Ipamorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Ipamorelin and Modafinil?
Ipamorelin and Modafinil differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Ipamorelin or Modafinil?
Ipamorelin half-life is 2 hours; Modafinil half-life is 13 hours.
Can you stack Ipamorelin with Modafinil?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper